COMy 2022 | Emerging therapies for Waldenström’s macroglobulinemia: HCK and IRAK inhibitors
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses novel and innovative therapies being investigated for the treatment of Waldenström’s macroglobulinemia (WM), including HCK inhibitors and IRAK inhibitors, and their future role in the treatment of MYD88-mutated WM. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Transcript (edited for clarity)
Well, I think we’re just at the beginning chapters of a very, very long book. And I think thanks to genomics more innovative therapies are coming down the pike, including those that have been developed in the laboratory. We’ll be seeing the more of HCK inhibitors, because we understand they’re very important in MYD88 signaling. We’re going to be seeing more of IRAK inhibitors, particularly in combination with BTK inhibitors, because they’re part of the MYD88 cascade...
Well, I think we’re just at the beginning chapters of a very, very long book. And I think thanks to genomics more innovative therapies are coming down the pike, including those that have been developed in the laboratory. We’ll be seeing the more of HCK inhibitors, because we understand they’re very important in MYD88 signaling. We’re going to be seeing more of IRAK inhibitors, particularly in combination with BTK inhibitors, because they’re part of the MYD88 cascade. And what I think is really exciting now is all the novel technologies that are being developed that can specifically target proteins, and MYD88 still represents public enemy number one in this disease, and so these kind of efforts are to be lauded, because I think they will genuinely lead to new drug treatments for this disease.
Read more...
Disclosures
Research support, consulting and/or honoraria received from: Abbvie/Pharmacyclics, Beigene, BMS, Eli Lilly, Janssen Pharmaceuticals, X4 Pharmaceuticals. IP assigned to DFCI for MYD88, CXCR4, and IRAK and HCK and other inhibitors.
